Skip to content
2000
Volume 7, Issue 3
  • ISSN: 1389-2029
  • E-ISSN: 1875-5488

Abstract

In Gram-negative pathogens, β-lactamase production remains the most important contributing factor to β- lactam resistance. β-lactamases are bacterial enzymes that inactivate β-lactam antibiotics by hydrolysis, which results in ineffective compounds. The three major groups usually referred to as the "newer β-lactamases" are plasmid-mediated AmpC enzymes, extended-spectrum β-lactamases (ESBLs) and carbapenem-hydrolyzing enzymes (including metallo-β- lactamases [MBLs]). Molecular methods that include simple and multiplex PCR, real-time PCR, DNA sequencing and various hybridization-based techniques are used widely in research and reference laboratories for the detection of organisms producing newer β-lactamases. The routine screening in clinical diagnostic laboratories of organisms producing TEM, SHV and OXA types of ESBLs using genotypic methods remains problematic, while the detection of CTX-Ms, plasmid-mediated AmpCs and MBLs shows clinical usefulness. Molecular methods have advantages over phenotypic tests by accurately detecting resistant genes in a rapid fashion and by defining the precise genetic basis of the resistance mechanism providing important information valuable to the early introduction of infection control practices. Molecular assays have the potential to complement conventional phenotypic susceptibility techniques and impact directly on patient care.

Loading

Article metrics loading...

/content/journals/cg/10.2174/138920206777780238
2006-05-01
2025-05-25
Loading full text...

Full text loading...

/content/journals/cg/10.2174/138920206777780238
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test